Allison DeLong, Mayla Hsu & Harriet Kotsoris
For the past 14 years, Allison DeLong, MS, has worked as a biostatistician at the Center for Statistical Sciences in the School of Public Health at Brown University. She has participated in numerous biomedical research studies and co-authored many peer-reviewed publications. The majority of her work centers around the diagnosis and treatment of infectious and non-communicable diseases in hard to reach populations or resource-limited settings. She has served on the scientific advisory board for the Global Lyme Alliance since 2007.
As Director of Research and Science at Global Lyme Alliance, Mayla Hsu, Ph.D. is responsible for grant review and oversight as well as scientific strategy. She was trained in molecular virology and has published peer-reviewed articles related to infectious disease, while in academia, the pharmaceutical industry, and at an NGO. She has been at Global Lyme Alliance for three years.
Harriet Kotsoris, M.D. is a board-certified internist and neurologist, whose clinical practice dealt with the neurological complications of tick-borne diseases. She later served as Chief Science Officer at Global Lyme Alliance from 2007-2017. She currently serves on a scientific advisory board at a foundation that supports tick-borne disease research.
As Director of Research and Science at Global Lyme Alliance, Mayla Hsu, Ph.D. is responsible for grant review and oversight as well as scientific strategy. She was trained in molecular virology and has published peer-reviewed articles related to infectious disease, while in academia, the pharmaceutical industry, and at an NGO. She has been at Global Lyme Alliance for three years.
Harriet Kotsoris, M.D. is a board-certified internist and neurologist, whose clinical practice dealt with the neurological complications of tick-borne diseases. She later served as Chief Science Officer at Global Lyme Alliance from 2007-2017. She currently serves on a scientific advisory board at a foundation that supports tick-borne disease research.
Prevalence of post-treatment Lyme disease in the United States — what can we expect?
While most patients recover form Lyme disease, a proportion do not respond to treatment and develop persistent symptoms such as chronic pain, cognitive dysfunction, and debilitating fatigue, classified as post-treatment Lyme disease PTLD. We currently don’t know how many people are living with PTLD, so new research published in BMC Public Health investigates this by using mathematical modeling predict prevalence in the US.
The incidence of Lyme disease, caused by tick-borne Borrelia burgdorferi bacteria, has now reached epidemic proportions in the US. There are an estimated 400,000 cases per year, with numbers rising due to climate change and habitat expansion of the tick vector. Early symptoms include skin rash, fever, and joint pain. With timely diagnosis and antibiotic treatment, most patients recover.
.png)
No hay comentarios:
Publicar un comentario